Most currently available anti-staphylococcal agents act only poorly on intracellular SCVs, unless upon prolonged exposure.
INTRODUCTION
Small Colony Variants (SCVs) of S. aureus have been associated with persistence of infection in cystic fibrosis (CF) patients, osteomyelitis, and device-related infections (1). They are characterized by an altered metabolic state, with most conspicuous changes consisting of a slower growth rate, a reduced production of α-hemolysin, and auxotrophy towards thymidine (thymidine-dependent SCVs) or hemin (hemin-dependent SCVs). Compared with their wild-type counterparts, SCVs persist more easily within host cells, where they are protected from host defenses and antibiotics (2) .
Being relatively unstable, SCVs can revert to normally virulent, rapidly growing phenotype, and cause host cell lysis, contributing therefore to the recurrence of infection.
It seems, therefore, important to evaluate antibiotic activity against intracellular forms of SCVs in order to select appropriate therapy.
AIM OF THE STUDY
To compare the intracellular activity of a series of antibiotics against a stable, thymidinedependent SCV variant of a CF mecA-negative isolate of S. aureus. To this effect, we used a model of infection in THP-1 human macrophages and antibiotic concentrations mimicking the C max reached in patients undergoing therapy with conventional dosages.
METHODS
Bacteria: we used a CF clinical isolate with stable thymidine auxotrophic SCV phenotype (3), growing as tiny, non-pigmented and non-hemolytic colonies on sheep blood agar. This strain was grown aerobically on Muller Hinton II medium (Becton Dickinson) with low and controlled content of thymidine.
Susceptibility testing: MICs were determined by microdilution method in Muller Hinton broth and MICs were read after 48 h of incubation.
Intracellular activity: infection of THP-1 macrophages was performed as previously described (4), with one hour phagocytosis (4 bacteria/cell), followed by a washing with 50 mg/L gentamicin (to eliminate extracellular bacteria) and reincubation in fresh medium containing either the tested antibiotic or gentamicin at its MIC (0.125 mg/L; control). Intracellular activity was measured after 24 h and 72 h exposure to antibiotics at a concentration corresponding to their respective human C max . Results are expressed as changes in postinfection inoculum (∆ log CFU/mg cell protein; CFU counting determined after 48 h incubation of cell lysates plated on brain heart infusion agar.)
Influence of thymidine on intracellular growth and intracellular activity of antibiotics. Background: SCVs of S. aureus are frequently isolated from cystic fibrosis patients (CF). Bacteria with this phenotype persist intracellularly, contributing to the chronic and recurrent character of the infection. We have examined the activity of commonly-recommended (and 1 experimental) antistaphylococcal antibiotics (AABs) against SCVs in human macrophages.
RESULTS

CONCLUSIONS
Methods:
We used a CF's clinical thymidine-auxotrophic mecA negative SCV isolate with a stable phenotype. MICs were measured by microdilution in MHB (reading at 48 h). Intracellular activities were determined after phagocytosis by human THP-1 macrophages (changes in post-phagocytosis inoculum [delta log CFU] after 24 and 72 h in cells incubated with AABs at an extracellular concentration corresponding to their respective most commonly reported Cmax).
Results:
At 24 h, intracellular growth was minimal and most AABs showed only a bacteriostatic effect, with TGC, MXF and RIF causing a 1 log decrease, and only ORI approaching a bactericidal effect (defined as 3 log CFU decrease). The activity of all drugs (except TGC) markedly progressed over time, with Q-D, MXF, RIF and ORI approaching or exceeding the limit of bactericidal effect at 72 h. Addition of thymidine (100 µg/mL) did not enhance activity except for Q-D (-1.55 ± 0.12 at 24h).
Conclusion:
Most registered AABs act only poorly on intracellular SCVs unless cells are exposed for prolonged times to them, which may explain the difficulty of eradicating these organisms in CF patients. Yet, RIF and MXF proved the most efficient among commonly recommended AABs. Because of its fast eradicating activity, ORI warrants being further studied in this and other related models of difficult-to-treat intracellular staphylococcal infections. Because the SCV used in this study is thymidine-dependent, we repeated the same experiments in medium supplemented with 100 µg/ml of thymidine and limiting the observation period to 24 h.
In this condition, the intracellular growth of the bacteria was restored, but the activity of antibiotics at 24 h was not significantly modified, except for quinupristin-dalfopristin (see figure) .
At 24 h, bacterial growth was minimal the majority of antibiotics caused only a modest decrease in bacterial counts (< 1 log decrease for vancomycin, quinupristin-dalfopristin, oxacillin, clindamycin, daptomycin, linezolid, and gentamicin) tigecycline, moxifloxacin, and rifampin achieved ≈ 1 log decrease only oritavancin achieved ≥ 2 log decrease 
